Ingelise J. Gordon

National Institute of Allergy and Infectious Diseases

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 22 papers. Top paper: “A Monoclonal Antibody for Malaria Prevention”.

A Monoclonal Antibody for Malaria Prevention

New England Journal of Medicine(2021)10.1056/nejmoa2034031

N/A

5.5DataRank · unranked

160 citations

Nina M. Berkowitz, Azza H. Idris, Emily E. Coates, LaSonji A. Holman, Floreliz Mendoza +33 more

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

The Lancet(2023)10.1016/s0140-6736(22)02400-x

N/A

4.3DataRank · unranked

65 citations

Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Christine Lee, Anne Preston +50 more

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Nature Medicine(2022)10.1038/s41591-021-01660-8

N/A

3.6DataRank · unranked

165 citations

Grace Chen, Cristina Carter, Michelle C. Crank, Thuy Nguyen, Maria Claudia Burgos Florez +70 more

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

New England Journal of Medicine(2022)10.1056/nejmoa2203067

N/A

3.6DataRank · unranked

125 citations

Azza H. Idris, Nina M. Berkowitz, Myra Happe, Martin R. Gaudinski, Christian Buettner +42 more

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

The Lancet Respiratory Medicine(2021)10.1016/s2213-2600(21)00098-9

N/A

2.5DataRank · unranked

67 citations

Kaitlyn M. Morabito, Emily Phung, Michelle C. Crank, Pamela Costner, LaSonji A. Holman +74 more

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Science Translational Medicine(2023)10.1126/scitranslmed.ade4790

N/A

1.9DataRank · unranked

96 citations

Amelia R. Hofstetter, Katherine V. Houser, Seemal F. Awan, Grace Chen, Maria Claudia Burgos Florez +95 more

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

The Lancet Infectious Diseases(2023)10.1016/s1473-3099(22)00793-9

N/A

1.2DataRank · unranked

41 citations

Andrea A. Berry, Kaitlin Mason, Azza H. Idris, Mark O’Callahan, Myra Happe +95 more

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

The Lancet Infectious Diseases(2022)10.1016/s1473-3099(22)00052-4

N/A

1.1DataRank · unranked

39 citations

Srilatha Edupuganti, Grace Chen, Myra Happe, Larisa Strom, Alicia T. Widge +67 more

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

The Lancet Infectious Diseases(2023)10.1016/s1473-3099(23)00344-4

N/A

1.0DataRank · unranked

24 citations

Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Prossy Naluyima, Francis Kiweewa +70 more

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Science(2021)10.1126/science.abh1766

N/A

0.807DataRank · unranked

216 citations

Tongqing Zhou, Yi Zhang, Eun Sung Yang, Chaim A. Schramm, Wei Shi +53 more

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

Nature Communications(2022)10.1038/s41467-022-35456-2

N/A

0.561DataRank · unranked

41 citations

Maryam Musayev, Timothy S. Johnston, Danielle A. Wagner, Amy R. Henry, Lingshu Wang +51 more

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.02.25.432969

N/A

0.510DataRank · unranked

29 citations

Tongqing Zhou, Yi Zhang, Eun Sung Yang, Chaim A. Schramm, Wei Shi +42 more

Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients

Frontiers in Immunology(2021)10.3389/fimmu.2021.615102

N/A

0.483DataRank · unranked

24 citations

Morgan R. Timm, Bharat Madan, Katherine E. Burgomaster, Kimberly A. Dowd, Erica Normandin +16 more

Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS

JCI Insight(2024)10.1172/jci.insight.175375

N/A

0.404DataRank · unranked

7 citations

Amarendra Pegu, Larisa Strom, Cristina Carter, Cynthia S. Hendel, LaSonji A Holman +32 more

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults

The Lancet HIV(2025)10.1016/s2352-3018(25)00041-4

N/A

0.335DataRank · unranked

8 citations

Katherine V. Houser, Martin R. Gaudinski, Alicia T. Widge, Seemal F. Awan, Cristina Carter +95 more

Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses

Research Square(2025)10.21203/rs.3.rs-7997313/v1

N/A

0DataRank · unranked

0 citations

Christian K. O. Dzuvor, Sydney P. Moak, L McManus, Abigail Thomas, Abigail E. Dzordzorme +9 more

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization

medRxiv(2021)10.1101/2021.12.15.21267805

N/A

0DataRank · unranked

129 citations

Xiaoying Shen, Stephen D. Schmidt, Sijy O’Dell, Charlene McDanal, Wenhong Feng +31 more

Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

Blood(2022)10.1182/blood.2022015721

N/A

0DataRank · unranked

25 citations

Ruba Shalhoub, Stephanie N. Rogers, Shiqin Yu, Muxin Gu, Margarete A. Fabre +39 more

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.28.486152

N/A

0DataRank · unranked

5 citations

Maryam Musayev, Timothy S. Johnston, Danielle A. Wagner, Amy R. Henry, Lingshu Wang +49 more

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

npj Vaccines(2024)10.1038/s41541-024-00959-0

N/A

0DataRank · unranked

21 citations

Amelia R. Hofstetter, Pamela Costner, LaSonji A Holman, Cynthia S. Hendel, Alicia T. Widge +95 more

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

npj Vaccines(2024)10.1038/s41541-024-00833-z

N/A

0DataRank · unranked

19 citations

Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik +93 more

Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses

Nature Microbiology(2025)10.1038/s41564-025-02137-x

N/A

0DataRank · unranked

5 citations

Gray Freeman, Adrian Creanga, Matthew J. Vukovich, Tek Narsingh Malla, Grace Mantus +29 more